14 DAY TRIAL // The Drug Information Association (DIA) will be conducting its 22nd annual EuroMeeting in Monaco, between March 8-10, organizers announce. According to the program that was made available, and detailed in a press release, a large number of topics will be covered by an extensive audience. A variety of hot topics of wide interest will be discussed as well, with about 3,300 professionals from the biopharmaceutical industry, contract service organizations, regulatory agencies, health ministries and academia scheduled to attend. This will be the second-largest DIA event of the year. The 46th annual meeting will take place in Washington DC later this year, between June 14-17.
According to organizers, the European conference will span 13 themes, for a total of about 110 topics, including, but not being limited to personalized medicine, informing patients, the future of health regulations, current approaches to medicine and biotechnology, and so on. Issues such as how innovation will shape the coming approaches to patient care, and how drugs will be screened, tested and assessed will also be discussed, with many experts scheduled to host debates, or present their own studies on these matters.
“We are confident that we have identified interesting and thought-provoking topics for the themes that will create a lively platform to debate the development and market access of medicines in Europe,” Kerstin Franzen, the co-chair of the EuroMeeting, says. She is also the senior director of the Pfizer Regulatory Policy & Intelligence department. Key speakers scheduled to hold presentations include experts from the European Medicines Agency, the US Food and Drug Administration (FDA), the European Commission, and other regulatory agencies throughout the Europe Union and beyond.
“The program committee believes all attendees can play a key role in building the success of the EuroMeeting and ensuring its place as one of the most important European conferences for professionals involved in the development of medicines,” Bruno Flamion, also a co-chair of the EuroMeeting, adds. He is also a professor of clinical pharmacology at the University of Namur, in Belgium, and the chair of the Scientific Advice Working Party at the European Medicines Agency (EMA).
The DIA is a neutral, global, professional, member-driven association of nearly 18,000 biotechnology, pharmaceutical, clinical research, academic and regulatory professionals and patient representatives. Through its international meetings, training courses, online learning and myriad of networking opportunities, the DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well-being worldwide.